Travere Therapeutics Inc
TVTX29.710USD
+0.240+0.81%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
2.66BMarket Cap
LossP/E TTM
More Details of Travere Therapeutics Inc Company
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Travere Therapeutics Inc Info
Ticker SymbolTVTX
Company nameTravere Therapeutics Inc
IPO dateJul 23, 2003
CEODube (Eric M)
Number of employees385
Security typeOrdinary Share
Fiscal year-endJul 23
Address3611 Valley Centre Dr
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92130
Phone18889697879
Websitehttps://travere.com/
Ticker SymbolTVTX
IPO dateJul 23, 2003
CEODube (Eric M)
Company Executives of Travere Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Eric M. Dube, Ph.D.
Dr. Eric M. Dube, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
143.42K
-100087.00%
Mr. Jeffrey A. Meckler
Mr. Jeffrey A. Meckler
Independent Director
Independent Director
81.00K
+6500.00%
Mr. Peter Heerma
Mr. Peter Heerma
Chief Commercial Officer
Chief Commercial Officer
78.99K
-7310.00%
Dr. William E Rote, Ph.D.
Dr. William E Rote, Ph.D.
Chief Research Officer
Chief Research Officer
55.05K
-12446.00%
Ms. Elizabeth E. Reed
Ms. Elizabeth E. Reed
Chief Legal Officer, General Counsel and Corporate Secretary
Chief Legal Officer, General Counsel and Corporate Secretary
54.83K
-10169.00%
Mr. Gary A. Lyons
Mr. Gary A. Lyons
Independent Chairman of the Board
Independent Chairman of the Board
51.00K
+6500.00%
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Director
Independent Director
49.00K
--
Dr. Jula Inrig, M.D.
Dr. Jula Inrig, M.D.
Chief Medical Officer
Chief Medical Officer
41.83K
-8735.00%
Dr. Roy D. Baynes, M.D., Ph.D.
Dr. Roy D. Baynes, M.D., Ph.D.
Independent Director
Independent Director
31.00K
+6500.00%
Mr. John A. Orwin
Mr. John A. Orwin
Independent Director
Independent Director
28.88K
+6500.00%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Eric M. Dube, Ph.D.
Dr. Eric M. Dube, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
143.42K
-100087.00%
Mr. Jeffrey A. Meckler
Mr. Jeffrey A. Meckler
Independent Director
Independent Director
81.00K
+6500.00%
Mr. Peter Heerma
Mr. Peter Heerma
Chief Commercial Officer
Chief Commercial Officer
78.99K
-7310.00%
Dr. William E Rote, Ph.D.
Dr. William E Rote, Ph.D.
Chief Research Officer
Chief Research Officer
55.05K
-12446.00%
Ms. Elizabeth E. Reed
Ms. Elizabeth E. Reed
Chief Legal Officer, General Counsel and Corporate Secretary
Chief Legal Officer, General Counsel and Corporate Secretary
54.83K
-10169.00%
Mr. Gary A. Lyons
Mr. Gary A. Lyons
Independent Chairman of the Board
Independent Chairman of the Board
51.00K
+6500.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
FILSPARI
90.90M
80.34%
Tiopronin Products
22.25M
19.66%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
FILSPARI
90.90M
80.34%
Tiopronin Products
22.25M
19.66%
Shareholding Stats
Updated: Sun, Dec 7
Updated: Sun, Dec 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
11.85%
Armistice Capital LLC
7.52%
BlackRock Institutional Trust Company, N.A.
7.45%
The Vanguard Group, Inc.
7.03%
Nomura Investment Management Business Trust
5.57%
Other
60.59%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
11.85%
Armistice Capital LLC
7.52%
BlackRock Institutional Trust Company, N.A.
7.45%
The Vanguard Group, Inc.
7.03%
Nomura Investment Management Business Trust
5.57%
Other
60.59%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.07%
Investment Advisor/Hedge Fund
33.80%
Hedge Fund
26.12%
Private Equity
5.46%
Research Firm
3.98%
Venture Capital
1.30%
Individual Investor
0.91%
Pension Fund
0.40%
Bank and Trust
0.38%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
480
104.98M
117.33%
-17.66M
2025Q3
458
107.07M
119.68%
-12.73M
2025Q2
470
104.47M
117.23%
-11.51M
2025Q1
484
101.83M
114.67%
-16.19M
2024Q4
461
96.91M
109.26%
-9.67M
2024Q3
448
85.09M
109.18%
-32.25M
2024Q2
444
90.35M
118.12%
-28.07M
2024Q1
437
90.02M
118.29%
-22.39M
2023Q4
428
87.89M
116.97%
-15.26M
2023Q3
417
84.96M
113.19%
-18.05M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
10.60M
11.85%
-740.20K
-6.53%
Sep 30, 2025
Armistice Capital LLC
6.72M
7.52%
-2.15M
-24.25%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
6.67M
7.45%
-23.17K
-0.35%
Sep 30, 2025
The Vanguard Group, Inc.
6.59M
7.37%
+619.09K
+10.36%
Sep 30, 2025
Nomura Investment Management Business Trust
4.98M
5.57%
-113.15K
-2.22%
Sep 30, 2025
Perceptive Advisors LLC
4.50M
5.02%
+701.00K
+18.47%
Oct 06, 2025
Adage Capital Management, L.P.
3.55M
3.97%
+768.00K
+27.59%
Sep 30, 2025
Emerald Advisers LLC
3.35M
3.74%
+114.92K
+3.55%
Sep 30, 2025
State Street Investment Management (US)
3.22M
3.6%
-265.34K
-7.62%
Sep 30, 2025
Fidelity Management & Research Company LLC
2.52M
2.82%
+1.67M
+195.17%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Invesco Pharmaceuticals ETF
5.39%
Innovator IBD 50 Fund ETF
4.05%
Virtus LifeSci Biotech Products ETF
3.77%
Invesco Dorsey Wright Healthcare Momentum ETF
2.96%
Franklin Genomic Advancements ETF
1.51%
ALPS Medical Breakthroughs ETF
1.44%
First Trust Small Cap Growth AlphaDEX Fund
1%
State Street SPDR S&P Biotech ETF
0.77%
First Trust Multi-Manager Small Cap Opportunities ETF
0.73%
Direxion Daily S&P Biotech Bull 3X Shares
0.48%
View more
Invesco Pharmaceuticals ETF
Proportion5.39%
Innovator IBD 50 Fund ETF
Proportion4.05%
Virtus LifeSci Biotech Products ETF
Proportion3.77%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion2.96%
Franklin Genomic Advancements ETF
Proportion1.51%
ALPS Medical Breakthroughs ETF
Proportion1.44%
First Trust Small Cap Growth AlphaDEX Fund
Proportion1%
State Street SPDR S&P Biotech ETF
Proportion0.77%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.73%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.48%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
